Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 12/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.53 |
| ▸ | CHRNB3 | Q05901 | 12/20 | 0.53 |
| ▸ | CHRNA6 | Q15825 | 12/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994561 | 1.00 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25409415 | 1.00 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22169156 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24884312 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL608991 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL400513 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL7149386 | 0.89 | NR1H2 (0.49) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL18081207 | 0.87 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL5242607 | 0.87 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL5241504 | 0.87 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2509982-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071758-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071758-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | NR1H2 52/4885CHRNB2 3071/4885CHRNA3 2212/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | NR1H2 595/4885CHRNB2 980/4885CHRNA3 1221/4885 |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA3, CHRNA6 | NR1H2 348/4885CHRNB2 9/4885CHRNA3 2/4885 |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | CHRNA3, CHRNA2, CHRNA6 | NR1H2 208/4885CHRNB2 9/4885CHRNA3 1/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | NR1H2 2556/4885CHRNB2 4706/4885CHRNA3 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.